Mediolanum International Funds’s BioMarin Pharmaceuticals BMRN Stock Holding History

Mediolanum International Funds’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-137,675	Closed	-$7.44M	–	414
2025 Q3	$7.44M	Buy	137,675 +49,534	+56%	+$2.83M	0.08%	228
2025 Q2	$4.86M	Buy	88,141 +70,597	+402%	+$4.16M	0.06%	255
2025 Q1	$1.25M	Sell	17,544 -1,395	-7%	-$93.8K	0.02%	357
2024 Q4	$1.24M	Buy	+18,939	New	+$1.27M	0.02%	363

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Mediolanum International Funds's BMRN Position: Q4 2025 in Review

Mediolanum International Funds sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 137,675 shares — an estimated $7.44M sold.

Mediolanum International Funds first reported a position in BMRN in Q4 2024 and held it in 4 quarters. The position peaked at $7.44M in Q3 2025. 541 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

Mediolanum International Funds reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Mediolanum International Funds sold 137,675 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $7.44M.
Mediolanum International Funds first reported a position in BioMarin Pharmaceuticals in Q4 2024 and held it in 4 quarters.
Mediolanum International Funds's BioMarin Pharmaceuticals position peaked at $7.44M in Q3 2025.
541 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Mediolanum International Funds's 13F filing for Q4 2025, filed 9 Feb 2026.